Skip to main content

Ovarian Serous Adenocarcinoma clinical trials at UC Cancer

3 research studies open to eligible people

Showing trials for
  • Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible females ages 18 years and up

    Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

    at UC Davis UCSD

  • Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

    open to eligible people ages 18 years and up

    Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.

    at UCSF

  • Ribociclib and Letrozole Treatment in Ovarian Cancer

    open to eligible females ages 18 years and up

    The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

    at UCSF

Our lead scientists for Ovarian Serous Adenocarcinoma research studies include .

Last updated: